Saudi Arabia Vaccine Market Overview

Market Size in 2025: USD 536.7 Million

Market Forecast in 2034: USD 680.9 Million

Market Growth Rate 2026-2034: 2.68%

According to IMARC Group's latest research publication, "Saudi Arabia Vaccine Market Size, Share, Trends and Forecast by Product Type, Treatment Type, Technology, Route of Administration, Patient Type, Indication, Distribution Channel, End User, and Region, 2026-2034", the Saudi Arabia vaccine market size was valued at USD 536.7 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 680.9 Million by 2034, exhibiting a CAGR of 2.68% from 2026-2034.

Download a sample PDF of this report: https://www.imarcgroup.com/saudi-arabia-vaccine-market/requestsample

How AI is Reshaping the Future of the Saudi Arabia Vaccine Market

• AI speeds up vaccine development in Saudi Arabia via Vision 2030, using big data analytics and machine learning for quality control, slashing approval times under new SFDA rules.
• AI-powered clinical trial analytics market hits USD 150 million, boosting vaccine testing efficiency in Riyadh and Jeddah with pharma giants like IQVIA leading the charge.
• Vision 2030 integrates AI for predictive outbreak modeling, enhancing vaccine distribution and cutting supply chain risks through smart digital health platforms nationwide.
• Local biotech firms leverage AI for mRNA vaccine design, supported by SAR 1.5 billion in digital health funds, making production faster and more precise.
• AI-driven patient recruitment tools in trials reach over 200 studies, improving vaccine access equity via telemedicine in line with National Data and AI Strategy.

Saudi Arabia Vaccine Market Trends & Drivers:

Saudi Arabia's vaccine market is surging thanks to Vision 2030, which pumps massive resources into healthcare transformation and self-sufficiency. The government has rolled out nationwide immunization campaigns through the Ministry of Health, covering over 95% of the target population and reaching about 6 million people yearly, with expansions into adult shots for high-risk groups. Big investments like the SAR 500 million deal in 2023 with MODON and the Vaccine Industrial Company to build a manufacturing plant in Sudair City are cutting import reliance and positioning the Kingdom as a regional vaccine hub. Public awareness drives are also kicking in, making vaccines a everyday part of health routines in cities like Riyadh and Jeddah.

Local vaccine production is exploding as a key growth engine, backed by hefty government funding and smart partnerships. In March 2022, Saudi leaders announced a whopping USD 3.4 billion push into vaccine and biomedical sectors, fueling factories for everything from antigens to complex biologics. This ties straight into Vision 2030's biotech focus, with R&D centers popping up and collaborations bringing mRNA tech for flu and RSV vaccines approved by the SFDA. The adult vaccine segment alone hit USD 252.28 million recently, showing real demand as urban centers like Dammam and Jeddah get better access through upgraded clinics and digital tracking systems. These moves ensure steady supply during crises and slash costs long-term.

Emerging trends like multivalent vaccines and tech integration are really revving up the market. These combo shots, protecting against multiple strains, dominate Ministry of Health bulk buys and campaigns, especially in high-traffic pilgrimage spots like Makkah where meningitis risks run high. Digital health records and centralized registries are boosting compliance, while partnerships with global giants expand options for next-gen immunizations. The overall market clocks in around USD 536.7 million, with influenza and adult vaccines like hepatitis seeing strong uptake amid urban growth and aging populations. Private-public tie-ups, such as Riyadh's vaccine distribution collab, have already pushed out millions more doses efficiently.

Saudi Arabia Vaccine Industry Segmentation:

The report has segmented the market into the following categories:

Analysis by Product Type:

• Multivalent Vaccine
• Monovalent Vaccine

Analysis by Treatment Type:

• Preventive Vaccine
• Therapeutic Vaccine

Analysis by Technology:

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others

Analysis by Route of Administration:

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others

Analysis by Patient Type:

• Pediatric
• Adult

Analysis by Indication:

• Bacterial Diseases
  • Meningococcal Disease
  • Pneumococcal Disease
  • Diphtheria/Tetanus/Pertussis (DPT)
  • Tuberculosis
  • Haemophilus Influenzae (Hib)
  • Typhoid
  • Others
• Viral Diseases
  • Hepatitis
  • Influenza
  • Human Papillomavirus (HPV)
  • Measles/Mumps/Rubella (MMR)
  • Rotavirus
  • Herpes Zoster
  • Varicella
  • Japanese Encephalitis
  • Rubella
  • Polio
  • Rabies
  • Dengue
  • Others

Analysis by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Institutional Sales
• Others

Analysis by End User:

• Hospitals
• Clinics
• Vaccination Centers
• Academic and Research Institutes
• Others

Regional Analysis:

• Northern And Central Region
• Western Region
• Eastern Region
• Southern Region

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players.

Recent News and Developments in the Saudi Arabia Vaccine Market

• November 2025: Inotek builds GMP-ready vaccine facility, reducing import reliance and strengthening regional biotech capabilities.
• October 2025: CSL Seqirus partners with Saudi Health Ministry on cell-based flu vaccines, localizing production to cut imports and boost pandemic readiness.
• October 2025: MOH launches biotech partnerships at Global Health Exhibition, driving vaccine innovation and investment under Vision 2030.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302